DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Recent clinical trials have proven the cardiovascular benefits of new medications for
patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose
co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials
evaluating the efficacy and safety of dapagliflozin (nor any other SGLT2-inhibitor) to limit
cardiac remodeling in patients with acute myocardial infarction (AMI) and left ventricular
(LV) dysfunction.
Preventing cardiac remodeling, an established predictor of subsequent heart failure (HF) and
cardiovascular death, is likely to translate into benefit in reducing clinical events in
post-MI patients.